IVBXF Stock - Innovent Biologics, Inc.
Unlock GoAI Insights for IVBXF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $9.42B | $6.21B | $4.56B | $4.27B | $3.84B |
| Gross Profit | $7.91B | $4.40B | $3.63B | $3.70B | $3.46B |
| Gross Margin | 84.0% | 70.9% | 79.6% | 86.6% | 89.9% |
| Operating Income | $-755,872,000 | $-1,679,301,000 | $-3,122,846,000 | $-2,703,350,000 | $-557,185,000 |
| Net Income | $-94,631,000 | $-1,027,913,000 | $-2,179,270,000 | $-2,728,755,000 | $-998,421,000 |
| Net Margin | -1.0% | -16.6% | -47.8% | -63.9% | -26.0% |
| EPS | $-0.06 | $-0.66 | $-1.46 | $-1.88 | $-0.74 |
Innovent Biologics, Inc. operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, and manufacture of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases. Its principal drug candidate is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody for the treatment of cancer, Hodgkin's lymphoma, and esophageal carcinoma. The company also offers Byvasda for the treatment of several malignant tumors; Halpryza for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and Wegener's granulomatosis; Pemazyre for the treatment of adults with locally advanced or metastatic cholangiocarcinoma; Olverembatinib for the treatment of adult patients with tyrosine kinase inhibitor; and Cyramza to treat four different types of cancers. In addition, it engages in the development of IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein for ocular fundus disease; IBI-306, a human monoclonal antibody to treat hypercholesterolemia; IBI-310, a recombinant human anti CTLA-4 monoclonal antibody for liver cancer and renal cell carcinoma. Further the company develops IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors; IBI-326, a fully human BCMA-CAR T-cell therapy for the treatment of adults with relapsed or refractory multiple myeloma; IBI-376 for the treatment of recurrent or refractory follicular lymphoma; and IBI-112 for the treatment of psoriasis. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. The company has strategic collaborations with NeoCura Bio-Medical Technology Co. Ltd.; Roche Group; Ascentage Pharma Group International; Eli Lilly and Company; Roche Group; and Bolt Biotherapeutics, Inc. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.
Visit WebsiteEarnings History & Surprises
IVBXFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 24, 2026 | — | — | — | — |
Q3 2025 | Aug 27, 2025 | $0.03 | $0.07 | +173.3% | ✓ BEAT |
Q1 2025 | Mar 26, 2025 | $-0.03 | $0.03 | +179.4% | ✓ BEAT |
Q3 2024 | Aug 28, 2024 | $-0.03 | $-0.03 | +3.2% | ✓ BEAT |
Q1 2024 | Mar 20, 2024 | $-0.07 | $-0.08 | -12.5% | ✗ MISS |
Q2 2023 | Jun 30, 2023 | $-0.10 | $-0.01 | +87.4% | ✓ BEAT |
Q4 2022 | Dec 31, 2022 | $-0.17 | $-0.12 | +30.7% | ✓ BEAT |
Q2 2022 | Jun 30, 2022 | $-0.15 | $-0.10 | +36.4% | ✓ BEAT |
Q4 2021 | Dec 31, 2021 | $-0.14 | $-0.19 | -29.5% | ✗ MISS |
Q2 2021 | Jun 30, 2021 | $-0.04 | $-0.11 | -188.1% | ✗ MISS |
Q4 2020 | Dec 31, 2020 | $0.06 | $-0.04 | -172.0% | ✗ MISS |
Q2 2020 | Jun 30, 2020 | $-0.04 | $-0.07 | -53.7% | ✗ MISS |
Q4 2019 | Dec 31, 2019 | — | $-0.12 | — | — |
Q2 2019 | Jun 30, 2019 | — | $-0.09 | — | — |
Q4 2018 | Dec 31, 2018 | — | $-1.70 | — | — |
Q2 2018 | Jun 30, 2018 | — | $0.02 | — | — |
Q4 2017 | Dec 31, 2017 | — | $-0.53 | — | — |
Q2 2017 | Jun 30, 2017 | — | $-0.35 | — | — |
Q4 2016 | Dec 31, 2016 | — | $-0.03 | — | — |
Q2 2016 | Jun 30, 2016 | — | $-0.03 | — | — |
Latest News
Reported Earlier, Innovent Biologics Announces Closing Of Global Strategic Partnership With Takeda For IBI363 And IBI343, With Option On IBI3001, Including $1.2B Upfront And Up To $11.4B Total Deal Value
📈 PositiveReported Earlier, Takeda And Innovent Biologics Collaborate To Develop, Manufacture And Commercialize IBI363 IBI343 Worldwide Outside Greater China With U.S. Co-Commercialization
📈 PositiveFrequently Asked Questions about IVBXF
What is IVBXF's current stock price?
What is the analyst price target for IVBXF?
What sector is Innovent Biologics, Inc. in?
What is IVBXF's market cap?
Does IVBXF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to IVBXF for comparison